News
Novo Nordisk Confidence in China Stays Strong Despite Drop in Weight-Loss Drug Sales, New CEO Says
China has massive unmet medical needs, Mike Doustdar, who took over as CEO of Novo Nordisk today, after previously leading its global operations, said at a second-quarter earnings conference call yesterday. The Bagsværd-based company will continue to strengthen its market position in the world's second-largest healthcare market, he added.
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...
Novo Nordisk AS (NVO) reports significant sales and profit growth, driven by obesity care expansion and strategic ...
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Novo Nordisk's U.S.-listed shares shed a third of their value last week after the company cut its full-year outlook and named ...
Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback